Loading…
SALBUTAMOL is a brand name for Albuterol (also known as Salbutamol). The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Salbutamol Nebuliser Solution are indicated in adults, adolescents and children aged 4 years and above, see section
Verbatim from this product's MHRA label. Tap a section to expand.
2. Salbutamol Nebuliser Solution is indicated for use in the routine management of chronic bronchospasm unresponsive to conventional therapy and the treatment of acute severe asthma. 2. Posology and method of administration Salbutamol Nebuliser Solution is for inhalation use only, to be breathed in through the mouth, under the direction of a physician, using a suitable nebuliser, via a face mask or T piece or via an endotracheal tube.
To open the plastic ampoule, take a strip of ampoules from the foil pack, remove one ampoule, replacing the rest back in the foil pack, and replace the foil pack back in the carton. Hold the ampoule upright and open it by twisting off the top.
Squeeze the liquid into the solution holder of the machine. Private purchase of nebuliser devices for use at home to deliver rescue therapy for the acute treatment of asthma in children and adolescents is not recommended. Only specialists in respiratory medicine should initiate and clinically manage use of nebulisers and associated nebulised medicines at home for acute treatment of asthma in children and adolescents.
Children should be trained in the correct use of their device to deliver rescue therapy and use should be supervised by a responsible adult. Urgent medical assistance should be sought if worsening asthma symptoms are not relieved by rescue medicines, even if there is short-term recovery following use of prescribed nebulised medication.
The solution should not be injected or swallowed. 5 mg to 5 mg salbutamol up to four times a day. Up to 40 mg per day can be given under strict medical supervision in hospital.
Paediatric Population Children aged 12 years and over:
Dose as per adult population. 5mg to 5mg up to four times a day. Other pharmaceutical forms may be more appropriate for administration in children under 4 years old.
Infants under 18 months old:
Clinical efficacy of nebulised salbutamol in infants under 18 months is uncertain. As transient hypoxia may occur supplemental oxygen therapy should be considered. Salbutamol Nebuliser Solution is designed to be used undiluted. 9%w/v) for Nebulisation or sterile sodium chloride injection (normal saline) may be required.
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000) and very rare (<1/10,000). Very common and common events were generally determined from clinical trial data.
Rare, very rare and unknown events were generally determined from spontaneous data. 4) Vascular disorders Rare (>1/10,000, <1/1,000) Peripheral vasodilation Respiratory, thoracic and mediastinal disorders Very rare (>1/10,000) Paradoxical bronchospasm Gastrointestinal disorders Uncommon (>1/1,000, <1/100) Mouth and throat irritation Musculoskeletal and connective tissue disorders Uncommon (>1/1,000, <1/100) Muscle cramps *Reported spontaneously in post-marketing data therefore frequency regarded as unknown Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Salbutamol Nebuliser Solution must only be used by inhalation, to be breathed in through the mouth and must not be injected or swallowed. Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma.
Severe asthma requires regular medical assessment, including lung function testing, as patients are at risk of severe attacks and even death. Physicians should consider using the maximum recommended dose of inhaled corticosteroid and/or oral corticosteroid therapy in these patients.
Patients receiving treatment at home should seek medical advice if treatment with Salbutamol Nebuliser Solution becomes less effective. The dosage or frequency of administration should only be increased on medical advice. Patients being treated with Salbutamol Nebuliser Solution may also be receiving other dosage forms of short-acting inhaled bronchodilators to relieve symptoms.
, inhaled corticosteroids) should be advised to continue taking their anti-inflammatory medication even when symptoms decrease, and they do not require Salbutamol Nebuliser Solution. Increasing use of bronchodilators, in particular short-acting inhaled β2- agonists to relieve symptoms, indicates deterioration of asthma control, and patients should be warned to seek medical advice as soon as possible.
The patient should be instructed to seek medical advice if short-acting relief bronchodilator treatment becomes less effective or more inhalations than usual are required. g. higher doses of inhaled corticosteroid or a course of oral corticosteroid).
Overuse of short-acting beta-agonists may mask the progression of the underlying disease and contribute to deteriorating asthma control, leading to an increased risk of severe asthma exacerbations and mortality. , daytime symptoms, night- time awakening, and activity limitation due to asthma) for proper treatment adjustment as these patients are at risk for overuse of salbutamol.
1. Non-IV formulations of salbutamol must not be used to arrest uncomplicated premature labour or threatened abortion.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Albuterol in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Severe exacerbations of asthma must be treated in the normal way. Salbutamol should be administered cautiously to patients suffering from thyrotoxicosis. Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol.
There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischemia associated with salbutamol. g. ischemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease.
Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin. Salbutamol Nebuliser Solution should be used with care in patients known to have received large doses of other sympathomimetic drugs.
Potentially serious hypokalaemia may result from β2-agonist therapy, mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids, and diuretics.
Serum potassium levels should be monitored in such situations. In common with other β-adrenoceptor agonists, salbutamol can induce reversible metabolic changes such as increased blood glucose levels. Diabetic patients may be unable to compensate for the increase in blood glucose and the development of ketoacidosis has been reported.
Concurrent administration of corticosteroids can exaggerate this effect. 8). Increase in lactate levels may lead to dyspnoea and compensatory hyperventilation, which could be misinterpreted as a sign of asthma treatment failure and lead to inappropriate intensification of short-acting beta-agonist treatment.
It is therefore recommended that patients are monitored for the development of elevated serum lactate and consequent metabolic acidosis in this setting. A small number of cases of acute angle-closure glaucoma have been reported in patients treated with a combination of nebulised salbutamol and ipratropium bromide.
A combination of nebulised salbutamol with nebulised anticholinergics should therefore be used cautiously. Patients should receive adequate instruction in correct administration and be warned not to let the solution or mist enter the eye.
As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with an alternative presentation or a different fast-acting inhaled bronchodilator.
Salbutamol Nebuliser Solution should be discontinued, and if necessary a different fast-acting bronchodilator instituted for on-going use. This medicine contains less than 1mmol sodium (23mg) per dose, that is to say essentially ‘sodium-free’.